Gevokizumab
- Generic Name
- Gevokizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1129435-60-4
- Unique Ingredient Identifier
- QX3JU54GYQ
- Background
Gevokizumab has been used in trials studying the treatment of Acne Vulgaris, Osteoarthritis, Behcet's Uveitis, Pyoderma Gangrenosum, and Behcet's Disease Uveitis, among others. Gevokizumab acts as a modulator of cytokine imbalance in IL-1 mediated disease states. It has a very high binding affinity of 300fM and blocks the activation of IL-1 receptors.
- Associated Conditions
- -
- Associated Therapies
- -
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Phase 1
Active, not recruiting
- Conditions
- Colorectal CancerGastroesophageal CancerRenal Cell Carcinoma
- Interventions
- Drug: GevokizumabDrug: BevacizumabDrug: RamucirumabDrug: CabozantinibDrug: Modified FOLFOX6Drug: FOLFIRIDrug: Paclitaxel
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 167
- Registration Number
- NCT03798626
- Locations
- 🇺🇸
University of California LA, Los Angeles, California, United States
🇺🇸WA Uni School Of Med, Saint Louis, Missouri, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath